Skip to search formSkip to main contentSkip to account menu

Graft versus host disease prophylaxis/therapy

Known as: prophylaxis/therapy, graft versus host disease, prophylaxis/therapy, GVHD, GVHD 
Therapy to prevent or treat graft vs host disease.
National Institutes of Health

Related topics

Related topics

3 relations
Biological Response Modifier TherapyGraft-vs-Host DiseaseSupportive care

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2013
Highly Cited
2013
Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation.
New treatments are needed for B-cell malignancies persisting after allogeneic hematopoietic stem cell transplantation (alloHSCT… 
Highly Cited
2007
Highly Cited
2007
Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease.
We evaluated the efficacy of umbilical cord blood (UCB) in the setting of a nonmyeloablative regimen consisting of fludarabine… 
Review
2001
Review
2001
Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis.
PURPOSE Controversy exists as to whether the incidence of graft-versus-host disease (GVHD) is increased after peripheral-blood… 
Highly Cited
2000
Highly Cited
2000
Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells.
Peripheral blood stem cells (PBSC) obtained from granulocyte-colony stimulating factor (G-CSF)-mobilized donors are increasingly… 
Highly Cited
2000
Highly Cited
2000
Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group…
Peripheral blood cells are increasingly used in place of bone marrow as a source of hematopoietic stem cells for allogeneic… 
Highly Cited
1999
Highly Cited
1999
Transplantation of anergic histoincompatible bone marrow allografts.
BACKGROUND Successful allogeneic bone marrow transplantation relies on global immunosuppression or elimination of T cells. In… 
Highly Cited
1998
Highly Cited
1998
Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow…
We report the results of a phase III open-label, randomized, multicenter trial comparing tacrolimus/methotrexate to cyclosporine… 
Review
1990
Review
1990
A retrospective analysis of therapy for acute graft-versus-host disease: secondary treatment.
We have reviewed results of secondary therapy in 427 patients with acute graft-versus-host disease (GVHD) who did not have a… 
Highly Cited
1989
Highly Cited
1989
Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia.
To assess the influence of graft-versus-host disease (GVHD) on recurrent leukemia and survival after allogeneic marrow… 
Highly Cited
1983
Highly Cited
1983
Transplantation for severe combined immunodeficiency with HLA-A,B,D,DR incompatible parental marrow cells fractionated by soybean agglutinin and sheep red blood cells.
Three patients with severe combined immunodeficiency (SCID) received transplants of HLA haplotype-mismatched parental bone marrow… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)